MINK THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS, FIRST PRE-COMMERCIAL PRODUCT REVENUE FROM AGENT-797, RANDOMIZED ARDS TRIAL ADVANCING, AND ARPA-H SELECTION FOR DEPLOYABLE CELL THERAPIES

Reuters · 2d ago

Please log in to view news